ESSA Pharma Inc.
EPIX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $86 | $86 | $93 | $104 |
| Short-Term Investments | $24 | $28 | $27 | $23 |
| Receivables | $1 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $1 | $1 | $1 |
| Total Curr. Assets | $111 | $115 | $122 | $128 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $111 | $115 | $123 | $128 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $2 | $2 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1 | $1 | $2 | $1 |
| Total Curr. Liab. | $2 | $2 | $4 | $3 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $2 | $2 | $4 | $4 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $280 | $280 | $280 | $280 |
| Retained Earnings | -$227 | -$223 | -$217 | -$208 |
| AOCI | -$2 | -$2 | -$2 | -$2 |
| Other Equity | $58 | $59 | $58 | $55 |
| Total Equity | $109 | $114 | $119 | $125 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $111 | $115 | $123 | $128 |
| Net Debt | -$86 | -$86 | -$93 | -$103 |